Pasithea Therapeutics Corp. (KTTAW) Liabilities and Shareholders Equity (2020 - 2026)

Pasithea Therapeutics has disclosed Liabilities and Shareholders Equity across 7 years of filings, most recently posting $51.7 million for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 204.01% year-over-year to $51.7 million; the TTM figure through Jun 2026 stood at $181.9 million (up 174.12% YoY), while the FY2025 annual figure was $60.2 million, up 274.98% from the prior year.
• Liabilities and Shareholders Equity came in at $51.7 million for Q2 2026 at Pasithea Therapeutics, down from $56.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $60.2 million in Q4 2025 to a low of $13.6 million in Q3 2025.
• Average Liabilities and Shareholders Equity over 5 years is $34.7 million, with a median of $34.4 million recorded in 2023.
• Year-over-year, Liabilities and Shareholders Equity tumbled 53.7% in 2024 and jumped 284.44% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $45.2 million in 2022, then slumped by 42.19% to $26.1 million in 2023, then slumped by 38.49% to $16.1 million in 2024, then jumped by 274.98% to $60.2 million in 2025, then slipped by 14.16% to $51.7 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $51.7 million in Q2 2026, $56.4 million in Q1 2026, and $60.2 million in Q4 2025.